Correlation Between SAB Biotherapeutics and Cyclacel Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Cyclacel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Cyclacel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Cyclacel Pharmaceuticals, you can compare the effects of market volatilities on SAB Biotherapeutics and Cyclacel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Cyclacel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Cyclacel Pharmaceuticals.

Diversification Opportunities for SAB Biotherapeutics and Cyclacel Pharmaceuticals

-0.77

Correlation Coefficient

SAB Biotherapeutics  Cyclacel Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between SAB and Cyclacel is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Cyclacel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclacel Pharmaceuticals and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Cyclacel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclacel Pharmaceuticals has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Cyclacel Pharmaceuticals go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Cyclacel Pharmaceuticals

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 13.64 times more return on investment than Cyclacel Pharmaceuticals. However, SAB Biotherapeutics is 13.64 times more volatile than Cyclacel Pharmaceuticals. It trades about 0.11 of its potential returns per unit of risk. Cyclacel Pharmaceuticals is currently generating about -0.05 per unit of risk. If you would invest  5.39  in SAB Biotherapeutics on September 13, 2024 and sell it today you would earn a total of  1.61  from holding SAB Biotherapeutics or generate 29.87% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	75.3%
Values	Daily Returns

SAB Biotherapeutics  vs.  Cyclacel Pharmaceuticals

SAB Biotherapeutics

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Cyclacel Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with SAB Biotherapeutics and Cyclacel Pharmaceuticals

The main advantage of trading using opposite SAB Biotherapeutics and Cyclacel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Cyclacel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will offset losses from the drop in Cyclacel Pharmaceuticals' long position.

The idea behind SAB Biotherapeutics and Cyclacel Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.